These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 4007273)

  • 41. Considerations in performing virus spiking experiments and process validation studies.
    Darling AJ
    Dev Biol Stand; 1993; 81():221-9. PubMed ID: 8174806
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterizing biological products and assessing comparability following manufacturing changes.
    Chirino AJ; Mire-Sluis A
    Nat Biotechnol; 2004 Nov; 22(11):1383-91. PubMed ID: 15529163
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Product development of probiotics as biological drugs.
    Sutton A
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S128-32; discussion S144-51. PubMed ID: 18181718
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of fermentation on product consistency.
    Lubiniecki AS; Anumula K; Callaway J; L'Italien J; Oka M; Okita B; Wasserman G; Zabriskie D; Arathoon R; Builder S
    Dev Biol Stand; 1992; 76():105-15. PubMed ID: 1478331
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk reduction in biotherapeutic products.
    Ill CR; Dehghani H
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):296-304. PubMed ID: 19333875
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Follow-on biologics: challenges of the "next generation".
    Schellekens H
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv31-36. PubMed ID: 15827057
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
    Kozak RW; Golker CF; Stadler P
    Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Process changes and their effect on process evaluation for viral clearance.
    Marcus-Sekura C
    Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regulatory processes and three Rs alternatives.
    Milstien J
    Dev Biol (Basel); 2002; 111():15-9. PubMed ID: 12678220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety issues of animal products used in serum-free media.
    Merten OW
    Dev Biol Stand; 1999; 99():167-80. PubMed ID: 10404888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biological assays: their role in the development and quality control of recombinant biological medicinal products.
    Mire-Sluis AR; Gerrard T; Das RG; Padilla A; Thorpe R
    Biologicals; 1996 Dec; 24(4):351-62. PubMed ID: 9088552
    [No Abstract]   [Full Text] [Related]  

  • 52. Who Expert Committee on Biological Standardization.
    World Health Organization
    World Health Organ Tech Rep Ser; 2004; 926():1-109. PubMed ID: 15918537
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic stability: an issue of product quality.
    Burns N
    Biologicals; 1993 Jun; 21(2):145-6. PubMed ID: 8297594
    [No Abstract]   [Full Text] [Related]  

  • 54. Criteria for investigation of the product equivalence of monoclonal antibodies for therapeutic and in vivo-diagnostic use in case of introduction of changes in the manufacturing process.
    Schäffner G; Haase M; Giess S
    Biologicals; 1995 Sep; 23(3):253-9. PubMed ID: 8527127
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationships among product characterization, process validation and preclinical/clinical studies for well-characterized products.
    Lubiniecki AS
    Dev Biol Stand; 1998; 96():173-5; discussion 177-9. PubMed ID: 9890530
    [No Abstract]   [Full Text] [Related]  

  • 56. Assessing physical containment in recombinant DNA facilities.
    Fisher E; Lincoln DR
    Recomb DNA Tech Bull; 1984 Mar; 7(1):1-7. PubMed ID: 6328583
    [TBL] [Abstract][Full Text] [Related]  

  • 57. WHO Expert Committee on biological standardization.
    World Health Organ Tech Rep Ser; 2007; (941):1-340, back cover. PubMed ID: 18314862
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Re-processing strategies for biologicals API manufacturing processes.
    Opitz U
    Dev Biol (Basel); 2003; 113():101-4; discussion 115-6. PubMed ID: 14620858
    [TBL] [Abstract][Full Text] [Related]  

  • 59. WHO Expert Committee on Biological Standardization.
    Horowitz B; Minor P; Morgenthaler JJ; Burnouf T; McIntosh R; Padilla A; Thorpe R; van Aken WG;
    World Health Organ Tech Rep Ser; 2004; 924():1-232, backcover. PubMed ID: 15693660
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A total organic carbon analysis method for validating cleaning between products in biopharmaceutical manufacturing.
    Baffi R; Dolch G; Garnick R; Huang YF; Mar B; Matsuhiro D; Niepelt B; Parra C; Stephan M
    J Parenter Sci Technol; 1991; 45(1):13-9. PubMed ID: 2007965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.